Nurse Practitioner Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Ju Yung Kim

Nurse Practitioner, Primary Care Albuquerque, NM Nurse Practitioner

NPI 1487076220 CMS profile 10905918

2121 Juan Tabo Blvd Ne, Albuquerque, NM 87112

Open in the dashboard

General payments

$192

2 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Ju Yung Kim of Albuquerque, NM is reported in the CMS Open Payments database as having received $192 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $104 1
2021 General $89 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ju Yung Kim
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Ju Yung Kim were reported at $0. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Ju Yung Kim Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $89 $137 $39–$445 $132
2022 $104 $139 $44–$421 $149
2023 $0 $163 $53–$481 $160
2024 $0 $176 $54–$511 $164
2025 $0 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Novo Nordisk Inc $192 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Food and Beverage $192 2 payments
Products named General payments · program years 2021–2022
  1. RYBELSUS $192 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,082

Median for Nurse Practitioner: 389

Drug cost

$62,267

Median for Nurse Practitioner: $21,885

Branded share of claims

16.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 17 $19,047
Jardiance Empagliflozin Brand 15 $13,270
Ozempic Semaglutide Brand 14 $13,211
Arnuity Ellipta Fluticasone Furoate Brand 11 $5,754
Albuterol Sulfate Hfa Albuterol Sulfate Brand 43 $1,598
Losartan Potassium Generic 65 $740
Ventolin Hfa Albuterol Sulfate Brand 13 $715
Pregabalin Generic 16 $707
Levothyroxine Sodium Generic 63 $615
Atorvastatin Calcium Generic 79 $549

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$17,428

Medicare's payments for the services billed

Medicare patients

124

Average age 72

Services billed

310

86 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 50%
Diabetes 34%
Depression 27%
Osteoporosis 25%
Ischemic heart disease 19%
Chronic kidney disease 19%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record